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Cancer evolution is driven by a combination of genetic and epigenetic abnormalities; the crucial role of epigenetic gene regulation is indicated by the high frequency of mutations in key regulators of epigenetic marks, including DNA methylation [1] [2] [3] . As prostate cancer is characterized by a low frequency of somatic mutations 1 , disruption of epigenetic pathways is likely to have an important role in the disease. Aberrant DNA methylation patterns are universally found in prostate cancer and are known to frequently affect genes involved in cancer-related processes [4] [5] [6] . An important contributor to altered epigenetic patterns in prostate cancer is enhancer of zeste homolog 2 (EZH2), whose altered expression is linked to malignancy and poor prognosis [7] [8] [9] [10] [11] . As the catalytic subunit of the Polycomb repressive complex (PRC2), EZH2 controls gene silencing by mediating trimethylation of histone H3 at lysine 27 (H3K27me3). Overexpression contributes to tumor development in part by leading to chromatin condensation and transcriptional repression of a broad range of genes involved in proliferation, invasion and angiogenesis [12] [13] [14] .
In this work, we aimed to identify additional alterations to epigenetic regulators that contribute to poor prognosis in prostate cancer. We found that the epigenetic factor BAZ2A (also known as TIP5) is broadly overexpressed in prostate cancer. Alteration in BAZ2A levels is not caused by somatic structural or sequence variations but rather is likely due to post-transcriptional regulation involving loss of miR-133a. Interestingly, we found that BAZ2A cooperates with EZH2 to induce aberrant gene silencing in prostate cancer cell lines. BAZ2A overexpression is tightly associated with a prostate cancer subtype displaying CIMP in tumors and with prostate cancer recurrence in patients. Our results demonstrate that BAZ2A is a new biomarker that BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence Analysis of genomic and DNA methylation data from 12 EOPC samples 2 did not demonstrate a genetic or epigenetic explanation for BAZ2A upregulation, with a lack of copy number alterations (CNAs), loss of heterozygosity, single-nucleotide variations, structural variations and promoter demethylation at the BAZ2A locus. The lack of mutations and CNAs was also verified in TCGA data ( Supplementary  Fig. 2 ), suggesting a post-transcriptional cause for aberrant BAZ2A expression in prostate cancer. In silico prediction of microRNAs (miRNAs) for BAZ2A 22 indicated that there was a high potential that miR-133a targets the 3′ UTR of this gene (Supplementary Table 2 ). miR-133a is known to function as a tumor suppressor in several cancer types [23] [24] [25] and has recently been reported to suppress cell proliferation, migration and invasion when expressed in prostate cancer cells 26, 27 . We found that miR-133a levels were downregulated in the EOPC samples as well as in the TCGA and Brase data sets (Fig. 1c) . In analysis of luciferase reporter constructs containing the BAZ2A 3′ UTR sequence, miR-133a expression mediated reduced luciferase levels ( Supplementary Fig. 1b) , whereas a reporter construct with a mutated miR-133a binding site in the BAZ2A 3′ UTR did not show reduced luciferase levels with miR-133a expression (Fig. 1d) . Furthermore, miR-133a caused robust decreases in BAZ2A mRNA and protein levels, similar to those found using small interfering RNA (siRNA) targeting BAZ2A ( Fig. 1e and Supplementary Fig. 1c ). These data indicate that BAZ2A overexpression is typically not caused by somatic structural or sequence variations in prostate cancer but is rather likely due to post-transcriptional regulation involving loss of miR-133a.
BAZ2A paradoxically contributes to the proliferation and viability of metastatic prostate cancer cell lines BAZ2A and its role in rDNA repression via the establishment of silent epigenetic marks has been studied so far only in non-malignant cells 17, 19, 28 ; depletion of BAZ2A in NIH3T3 and COS cells caused (a) Box plots of BAZ2A expression in prostate cancer using patient-matched tumor-normal ratios available from TCGA (n = 28; left) and independent tumor (n = 51) and normal (n = 48) data from the Brase data set (right). Box plots represent the first and third quartiles and median values; whiskers represent the 5th and 95th percentiles. RSEM, RNA-seq by expectation maximization.
(b) BAZ2A is highly expressed in metastatic prostate cancer tissues. Expression profiles of BAZ2A and EZH2 from Gene Expression Omnibus (GEO) data sets GSE3325 and GSE6919 (gene expression microarray data). *P < 0.05, **P < 0.005, ***P < 0. A r t i c l e S loss of silencing epigenetic marks at rDNA, upregulation of rDNA transcription and an increase in ribosome production and cell proliferation, underscoring the intimate link between rRNA synthesis and cell proliferation 29, 30 . Consistent with these previous findings, knockdown of BAZ2A by siRNA in normal prostate epithelial RWPE1 cells increased rDNA transcription and slightly enhanced cell proliferation ( Fig. 2a and Supplementary Fig. 1d-f) . BAZ2A depletion instead slowed proliferation rates and reduced rDNA transcription in all tested metastatic prostate cancer cell lines, including PC3, DU145 and LNCaP cells, although BAZ2A maintained its role in the epigenetic regulation of rDNA in PC3 cells. The unexpected downregulation of rDNA transcription upon BAZ2A knockdown might reflect the defective cell proliferation known to affect and modulate the activity of the rDNA transcription machinery 31 . The unusual phenotypes observed upon BAZ2A knockdown in metastatic prostate cancer cells suggest that the role of BAZ2A in prostate cancer cells extends beyond the epigenetic control of the rDNA locus. Similarly to BAZ2A knockdown, depletion of EZH2 reduced the proliferation and viability of PC3 cells, underscoring the recognized oncogenic role of EZH2 in prostate cancer cells 7 ( Fig. 2b and Supplementary  Fig. 1g) . Remarkably, addition of miR-133a drastically impaired the proliferation of PC3 cells, whereas RWPE1 cells remained unaffected (Fig. 2c) .
No obvious changes in apoptosis and senescence were evident with BAZ2A knockdown in PC3 cells and in the non-malignant RWPE1 cell line (Supplementary Fig. 3a,b) . However, cell cycle analysis showed an accumulation of PC3 cells in G1 phase after BAZ2A depletion, whereas no detectable changes were observed in RWPE1 cells (Supplementary Fig. 3c ). In analysis of progression to S phase after the release of G1/S-synchronized PC3 cells, BAZ2A depletion induced a delay in progression in comparison to control PC3 cells and RWPE1 cells (Supplementary Fig. 3d ). Consistent with these results, only PC3 cells with BAZ2A knockdown increased the expression of negative cell cycle regulators such as CDKN1A ( Supplementary  Fig. 3e and Supplementary Tables 3 and 4) . Analysis of the invasion and migration of metastatic PC3 prostate cancer cells showed that these features of metastatic and aggressive prostate cancer were drastically impaired upon BAZ2A knockdown (Fig. 2d,e) . Previous studies demonstrated that the PC3 cell line retains a small fraction of cells (~1%) that can initiate serially transplantable tumors 32, 33 and can be distinguished by their ability to form holoclones, which are small, dense colonies with a high capacity for self-renewal 34, 35 . Remarkably, unlike control knockdown cells, PC3 cells stably depleted of BAZ2A were unable to form holoclones and meroclones (an intermediate phenotype of holoclones) and generated only paraclones, which retain no self-renewal capacity ( Fig. 2f and Supplementary Fig. 3f,g ).
Taken together, these results indicate that, in contrast to its role in non-malignant cells, BAZ2A paradoxically contributes to the proliferation and viability of metastatic prostate cancer cell lines and is implicated in a cancer cell-specific phenotype involving migration, invasion and stem cell-like features of prostate cancer, which are important in metastasis and disease recurrence 36 .
BAZ2A and EZH2 coordinate epigenetic silencing in prostate cancer cells
As the phenotypic analysis in prostate cancer cells suggested additional roles for BAZ2A that are rDNA independent, we reasoned that BAZ2A might regulate a class of non-rRNA genes that are critical for prostate cancer. Because of the various similarities between EZH2 and BAZ2A, we investigated global gene expression in PC3 prostate cancer cells depleted of BAZ2A or EZH2 using microarrays. In this analysis, the transcription of 1,921 genes was significantly upor downregulated after BAZ2A knockdown (log 2 fold difference = 0.58; P < 0.05), whereas depletion of EZH2 affected the expression of 1,793 genes (Fig. 3a,b and Supplementary Table 3) . Remarkably, about one-third of the genes regulated by BAZ2A were also 
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A r t i c l e S regulated by EZH2, a proportion not expected by chance (P = 2.2 × 10 −16 , calculated by a combination of permutation and Fisher tests), indicating that BAZ2A and EZH2 regulate hundreds of genes in common in PC3 cells. In further support of an rDNAindependent role for BAZ2A in prostate cancer, abundant amounts of BAZ2A were present in the nucleoplasmatic fraction of PC3 cells ( Supplementary Fig. 4 ), whereas all non-malignant mouse cells analyzed so far displayed an exclusive localization of BAZ2A within nucleoli, the nuclear compartment that contains rRNA genes ( Supplementary  Fig. 4 ). Gene set enrichment analysis (GSEA) uncovered a strong positive correlation with gene sets and pathways involved in metastasis (for example, extracellular matrix organization and collagen formation) and immune function (interferon and cytokine signaling) independently within both data sets (q < 0.05; Supplementary Fig. 5 and Supplementary Table 5 ). Furthermore, the aging and senescence gene set that was recently found to be a signature for indolent prostate cancer 37 was negatively correlated with genes regulated by BAZ2A or EZH2 (P < 0.01 for both). In comparison to experiments in PC3 cells, knockdown of BAZ2A or EZH2 in the non-malignant RWPE1 cell line resulted in an overlap of only 15% of genes, with only 16 of these genes having expression affected by both BAZ2A and EZH2 knockdown in PC3 cells (Fig. 3a,b and Supplementary Table 6) . Genes regulated by both BAZ2A and EZH2 in RWPE1 cells did not show any relevant gene ontology (GO) enrichment ( Supplementary  Fig. 6 ). Remarkably, the genes affected by BAZ2A depletion in PC3 and RWPE1 cells were implicated in distinct biological processes ( Supplementary Fig. 7 ). Taken together, these data show that BAZ2A and EZH2 coordinate shared biological pathways in PC3 prostate cancer cells that are not present in non-malignant RWPE1 cells, suggesting a functional BAZ2A-EZH2 cooperation that is specific for metastatic prostate cancer cells.
To determine how the transcriptional repressors BAZ2A and EZH2 might cooperate to regulate genes with likely roles in prostate cancer metastasis, we identified 101 genes that were downregulated in metastatic tumors in comparison to normal prostate tissues or primary tumors 7, 38 as well as upregulated upon BAZ2A or EZH2 knockdown in PC3 cells. We termed these genes RBEPMs (repressed by BAZ2A and EZH2 in prostate cancer cells and repressed in metastatic prostate cancer tumors) ( Fig. 3c and Supplementary Table 3) . Upregulation of the nine RBEPMs (AOX1, FBN1, FHL2, HOMER2, HOXA7, LAMB3, MKX, KLF6 and ZNF185) that showed the strongest downregulation in metastatic tumors ( Fig. 3c) and had previously been reported to be hypermethylated and transcriptionally repressed in cancers 4, [39] [40] [41] [42] [43] [44] [45] was validated in BAZ2A and EZH2 knockdown cells ( Fig. 3d and Supplementary Fig. 8a ). Analysis of RWPE1 cells confirmed that these RBEPMs were predominantly not normally regulated by BAZ2A and EZH2 (Fig. 3d and Supplementary Table 4) .
The substantial overlap of BAZ2A-and EZH2-regulated genes in PC3 cells prompted us to investigate the direct association and coordinated binding of BAZ2A and EZH2 at RBEPM promoters (Fig. 3d) . Coimmunoprecipitation of Flag-HA-BAZ2A from the nuclear extracts of HEK293T cells showed an association with EZH2 (Fig. 4a) 
A r t i c l e S that BAZ2A and EZH2 were generally more associated with RBEPM and rDNA promoters in PC3 cells than in RWPE1 cells (Fig. 4b) . Consistent with the BAZ2A and EZH2 binding profiles, H3K27me3 levels at RBEPM and rDNA promoter sequences were higher in PC3 cells than in RWPE1 cells, underscoring the role of histone repressive marks in transcriptional silencing at RBEPMs in prostate cancer cells (Fig. 4c) . A lack of evident additive RBEPM activation upon combined depletion suggests that BAZ2A and EZH2 repress the transcription of RBEPM genes via a shared pathway ( Fig. 4d and Supplementary Fig. 8b ). Accordingly, all RBEPMs showed decreased association with EZH2 upon BAZ2A depletion ( Fig. 4e and Supplementary Fig. 8c ). Similar results were obtained for BAZ2A binding with the majority of RBEPMs (with the exception of LAMB3 and KLF6) in PC3 cells in the absence of EZH2, indicating that the recruitment of EZH2 to RBEPM promoters is codependent on BAZ2A. Remarkably, depletion of BAZ2A decreased H3K27me3 levels and increased the association of the active histone mark H3K4me3 (trimethylation of histone H3 at lysine 4) with RBEPM and rDNA promoter sequences (Fig. 4f) . Taken together, the results show the essential role of BAZ2A in coordinating EZH2 recruitment and the establishment of H3K27 methylation at genes frequently repressed in metastatic prostate cancer. The data indicate that BAZ2A acts as epigenetic regulator for the transcriptional repression of genes that are implicated in aggressive prostate cancer.
Tumors with high BAZ2A expression display a CpG island hypermethylator phenotype Because BAZ2A is known to interact with DNA methyltransferases and this association is required to establish epigenetic silencing at rDNA in all cells 17 , we next investigated whether the upregulation of BAZ2A was associated with altered DNA methylation in prostate tumors. As we determined that BAZ2A was primarily regulated post-transcriptionally, we analyzed BAZ2A protein levels in prostate tumors and normal tissues using immunohistochemistry on a tissue microarray (TMA) of 384 samples. BAZ2A immunostaining was variable between prostate tumor specimens in comparison to normal prostate epithelium, with strong and weak staining in 21% and 25% of samples, respectively. We selected 22 tumors with high BAZ2A protein levels and 13 tumors with low BAZ2A protein levels for DNA methylation analysis using the Illumina Infinium HumanMethylation450 (450K) array. Samples were also selected to have >70% tumor content, which was confirmed to not appreciably differ between samples with high and low BAZ2A expression by observing between the groups consistent hypermethylation of GSTP1 (ref. 46 ) and APC 47 , genes known to 
H3K27me3 0.5 Relative occupancy A r t i c l e S be hypermethylated in early disease stages (Supplementary Fig. 9a ). Genome-wide analysis showed that the methylation of 32,707 CpGs was significantly altered (by more than ±20%; q < 0.05) in comparison to 6 normal prostate samples, with 24,497 and 8,210 CpGs hyper-and hypomethylated, respectively (Fig. 5a) . Unsupervised clustering of the 3,000 most variable of these CpGs identified 2 distinct DNA methylation subtypes. A statistical evaluation showed an optimal number of two distinct methylation subtypes (Fig. 5b) . To validate this finding, we independently interrogated TCGA prostate cancer data using the same approach of separating samples into those with high versus low BAZ2A expression (on the basis of available RNA expression data) and identifying de novo the 3,000 most variable probes (Supplementary Fig. 10 ). Ninety percent of the most variable CpGs were common to both analyses and furthermore identified two distinct methylation subgroups. One of the subtypes was characterized by a higher degree of hypermethylation of CpG islands (CGIs) and sites associated with Polycomb repression (as defined in LNCaP cells 48 ) while simultaneously demonstrating hypomethylation of repetitive elements (such as long interspersed nuclear elements, LINEs) (Fig. 5c) . The pattern present in this subtype is reminiscent of a CGI hypermethylator phenotype (CIMP) observed in other cancers [49] [50] [51] , as well as globally in prostate cancer 5, 52 . We observed a striking correlation between BAZ2A expression levels and the CIMP subtype, with 21 of 22 CIMP-positive samples displaying high BAZ2A levels and 12 of 13 normal-like samples exhibiting low BAZ2A levels. We also observed a similar association of the CIMP subtype with high BAZ2A expression in the analysis of TCGA data ( Supplementary  Fig. 10 ). Comparing tumors with high and low BAZ2A expression, in the subtype with high expression, 6,155 CpGs were hypermethylated and 1,679 CpGs were hypomethylated (difference in methylation of greater than ±20%). Hypermethylated CpGs were enriched in transcription factor binding and DNase-hypersensitive sites in addition to CGIs and CGI shore regions (Fig. 5d) . Hypermethylation in tumors with high BAZ2A levels was strongly enriched in Polycombsilenced regions (as defined in DU145 and LNCaP cells or primary prostate epithelial cells). Thus, elevated BAZ2A levels are associated with widespread epigenetic remodeling that includes functional regions, such as promoter and enhancer regions, and with Polycombassociated domains. Considering our findings connecting BAZ2A with EZH2 and H3K27me3 in PC3 prostate cancer cells, the observation of greater hypermethylation of H3K27me3-marked regions suggests that high BAZ2A overexpression might be involved in the 
A r t i c l e S establishment of abnormal methylation patterns in prostate tumors. Tumors with high BAZ2A levels were also associated with advanced tumor stages and higher Gleason scores. BAZ2A-associated alterations to DNA methylation were found to involve numerous genes and pathways that are known to be associated with prostate cancer in general (Supplementary Table 7) , including hypermethylation of prostate cancer-relevant gene promoters and miRNAs known to inhibit androgen receptor expression [53] [54] [55] [56] [57] [58] ( Supplementary Fig. 9b,c) . In comparison to the genes that become derepressed following BAZ2A knockdown in PC3 cells, 352 genes (35%) were found to have elevated levels of DNA methylation in tumors with high versus low BAZ2A expression, a number greater than expected by chance (P = 0.0029). There were 27 genes that were hypermethylated in tumors with high BAZ2A levels and upregulated upon both BAZ2A or EZH2 knockdown in PC3 cells (Fig. 5e,f) . Next, we performed GSEA on genes with differential promoter methylation in tumors with high and low BAZ2A levels ( Supplementary Fig. 11 and Supplementary Tables 7 and 8) . Several cellular pathways and functions that are relevant to cancer development were found to be significantly enriched (FDR q < 0.05), including cell growth (cell cycle and transcription pathways) and genome stability (chromosome and telomere maintenance pathways). These gene sets were also identified for the genes showing differential expression with BAZ2A knockdown in PC3 cells (Supplementary Fig. 5) . Moreover, hypermethylated genes in tumors with high BAZ2A levels and genes derepressed upon BAZ2A depletion in PC3 cells showed identical GO terms (Supplementary Fig. 12 ). Taken together, the data support a functional role for BAZ2A in DNA hypermethylation in prostate cancer tumors (Supplementary Fig. 12 ).
BAZ2A levels predict PSA recurrence in individuals with prostate cancer
We investigated the potential clinical relevance of BAZ2A in prostate cancer using a large TMA. This analysis included 7,682 informative samples for which clinical follow-up data were available. Case characteristics and clinical data are displayed in Supplementary Table 9 .
BAZ2A immunostaining in tumor samples was categorized as negative (26.1%), weak (36.7%), moderate (18.5%) or strong (19.0%) (as in Fig. 5 ; examples shown in Fig. 6a) . We observed nuclear localization of BAZ2A, including increased staining in nucleoli ( Fig. 6a and Supplementary Fig. 13 ). Strong BAZ2A staining was highly associated with advanced prostate tumor stage, high Gleason grade, the presence of lymph node metastasis, high preoperative PSA levels and positive surgical margin when considering all tumors or following subgrouping by ERG rearrangement status (P < 0.0001 for each; Supplementary Table 10a-c) . The time to postoperative PSA recurrence was significantly shorter in the group with strong BAZ2A expression (P < 0.0001; Fig. 6b ). Using Cox regression multivariate analysis to determine the relative dependence of recurrence on several prognostic and surgical parameters, the level of BAZ2A was determined to be independently predictive of PSA recurrence in multiple scenarios (P < 0.0001; Supplementary  Table 11a-c) . The independent predictive power of BAZ2A was further upheld following subdivision of the cases by ERG rearrangement status (P < 0.0001; Supplementary Fig. 14) . Notably, to answer the question of whether BAZ2A levels could be used as a marker to aid in preoperative therapy decision-making for low-and intermediaterisk cases, we subdivided the cases by Gleason score and compared the frequency of postoperative PSA recurrence. BAZ2A levels were significantly predictive of PSA recurrence in cases with a Gleason score of 3+4 (low-intermediate risk; n = 4,013, P = 0.0017) or 4+3 (high-intermediate risk; n = 1,096, P = 0.0059) (Fig. 6c) . BAZ2A levels did not show significant predictive ability in cases with a Gleason score of ≤3+3 (indolent prostate cancer; n = 1,690), likely owing to the occurrence of relatively very few events in this group, nor in very high-risk cases (Gleason score of ≥4+4; n = 322) (Supplementary Fig. 14) . These results demonstrate a clear association of BAZ2A levels in prostate cancer tumor samples with PSA recurrence that is independent of standard prognostic and surgical parameters and can distinguish cases that npg are ore likely to recur in the most uncertain group of individuals at intermediate risk.
DISCUSSION
Alterations involving epigenetic regulators are now recognized as key events governing the tumor cell phenotype by affecting the expression of genes critical to cancer. This work identified a new aberrant epigenetic signature (CIMP) that distinguishes prostate cancer tumors with high and low BAZ2A expression. Elevated BAZ2A levels associate with poor prognosis and disease recurrence, and tumors with high BAZ2A expression contain a specific set of hypermethylated genes implicated in several pathways relevant to cancer. We provide multiple lines of evidence that support the role of BAZ2A in the establishment of epigenetic alterations in cases with poor prognosis. Through the combined analysis of metastatic prostate cancer cell lines and tumor samples from patients, we found that the role of BAZ2A in prostate cancer goes beyond the epigenetic control of the rDNA locus. Using prostate cancer cell lines, we show that BAZ2A regulates genes (i) frequently repressed in metastatic prostate cancer and (ii) hypermethylated in prostate cancer cases with poor prognosis. The analysis of hypermethylated sequences in tumors with high BAZ2A expression identified an enrichment of sites associated with Polycomb repression that is in agreement with the results from the prostate cancer cell line describing the repression activity of BAZ2A in concert with Polycomb-based silencing. Furthermore, genes regulated by BAZ2A in prostate cancer cell lines and hypermethylated in tumors with high BAZ2A levels involve similar pathways and cancer-related processes.
A role for BAZ2A in establishing epigenetic alterations that might favor the aggressive prostate cancer phenotype is also supported by the phenotypic analysis in prostate cancer cell lines showing an impact of BAZ2A on cancer-specific features such as proliferation, migration and invasion. Future studies will aim to define how and at which time point in prostate cancer progression BAZ2A exerts its oncogenic effect. Notably, we showed that high expression of BAZ2A in prostate cancer is likely caused by post-transcriptional regulation, supporting the idea that the disruption of epigenetic pathways is likely to have an important role in this disease. Lethality in prostate cancer is linked to the evolution of a metastatic phenotype. PSA recurrence following radical prostatectomy signifies that tumor cells gained the ability to invade surrounding tissues and/or metastasize before surgery. Our results suggest that high BAZ2A levels in the primary tumor indicate a higher probability of metastasis, linking molecular findings with recurrence in clinical samples. We have shown BAZ2A levels to be an independent prognostic marker of recurrence, especially in low-and intermediaterisk cases, as assessed by Gleason score. Intermediate-risk cases are a subcohort with the most uncertainty in deciding the right balance between active surveillance and immediate definite therapy to avoid overtreatment. Screening of BAZ2A levels in biopsies might be a valuable biomarker to distinguish prostate cancer that may progress, aiding in the therapy decision-making for this important patient subgroup. Additionally, as an increasing number of epigenetic regulators, including members of the bromodomain-containing protein class, are currently being found to be dysregulated across many cancer types 59 , BAZ2A, which contains a bromodomain required for its silencing function at rDNA 60 assessment with the Agilent 2100 Bioanalyzer (Agilent Technologies), 1.6 µg of Cy3-labeled cRNA was hybridized to SurePrint G3 Human Exon 4x180K microarrays (Agilent Technologies) according to the manufacturer's protocol. Arrays were scanned with an Agilent G2565CA Microarray Scanner System (Scan Control Software 8.5, Agilent Technologies). Raw intensity data were obtained using Agilent's Feature Extraction Software version 10.7 for array image analysis and the calculation of spot intensity measurements. Data were analyzed with R Bioconductor. Between-array normalization was performed using quantile normalization. Differential expression was computed using the limma package. Heat maps were generated using the heatmap.2 function in the gplots package. Transcripts with a fold change of >1.5 or <0.66 (log 2 ±0.58) in cells expressing BAZ2A or EZH2 siRNA relative to control cells and P < 0.05 were considered to have a statistically significant difference in expression and were analyzed for GO enrichment using the Database for Annotation, Visualization and Integrated Discovery (DAVID) for the enrichment of GO terms.
Immunoprecipitation. Immunoprecipitation was performed by transfection of HEK293T cells with the expression vector pcDNA-Flag-HA-BAZ2A. Nuclear extracts were immunoprecipitated overnight at 4 °C using an immobilized antibody against Flag (Anti-FLAG M2 Affinity Gel, Sigma). Precipitates were washed three times with wash buffer (20 mM Tris-HCl (pH 7.8), 150 mM KCl, 5 mM MgCl 2 , 0.2 mM EDTA, 10% glycerol, 0.1% Tween and 0.1 mM PMSF), separated on a 6% SDS-polyacrylamide gel and analyzed by immunoblotting.
Chromatin immunoprecipitation. ChIP analysis was performed as previously described 63 . Briefly, 1% formaldehyde was added to cultured cells to crosslink proteins to DNA. Isolated nuclei were then lysed in 300 µl of lysis buffer (50 mM Tris-HCl (pH 8.1), 10 mM EDTA and 1% SDS) and sonicated using a Bioruptor ultrasonic cell disruptor (Diagenode) to shear genomic DNA to an average fragment size of 200 bp. Chromatin (20 µg) was diluted tenfold with immunoprecipitation buffer (16.7 mM Tris-HCl (pH 8.1), 167 mM NaCl, 1.2 mM EDTA, 0.01% SDS and 1.1% Triton X-100) and then immunoprecipitated overnight with the indicated antibodies. After washing, elution and reversion of cross-links, the precipitated DNA was purified with phenolchloroform, ethanol precipitated and quantified by quantitative PCR. Primer sequences and antibodies are listed in Supplementary Tables 12 and 13. DNA methylation data analysis. Prostate tumor samples were selected histologically to have >70% tumor content. DNA was isolated from formalinfixed paraffin-embedded material using the QIAamp DNA FFPE Tissue kit (Qiagen). DNA methylation analysis was performed using 450K BeadChip arrays (Illumina) according to the manufacturer's instructions. We extracted the raw methylation intensity data and performed subset quantile withinarray normalization (SWAN) 46 . Probes with a detection P value of <0.01 were excluded from further analysis. The 5,000 most variable probes were selected for k-means consensus clustering by the ConsensusClusterPlus package with Spearman distance and average linkage over 1,000 resampling iterations with random restart. The optimal number of clusters was determined by the CDF and consensus clustering. Hierarchical clustering was then performed to visualize the methylation patterns within 35 samples. Gene set enrichment analysis was performed using GSEA tools (version 2-2.0.13) with Molecular Signatures Databases (MSigDB version 4.0) from the Broad Institute as previous described 64 with modifications. Statistical enrichment of the intersection of the gene lists for differential methylation and expression was performed using random permutation.
Tissue microarrays. Radical prostatectomy specimens were obtained from 11,152 patients undergoing surgery between 1992 and 2011 at the Department of Urology and the Martini Clinics at the University Medical Center HamburgEppendorf. Follow-up data were available for a total of 9,628 patients, with a median follow-up of 36.8 months (range of 1 to 228 months; Supplementary Table 9) . PSA values were measured quarterly during the first 3 years and then biannually following surgery, and recurrence was defined as a postoperative PSA value of 0.2 ng/ml and increasing at first appearance. All prostate specimens were analyzed according to a standard procedure, including complete embedding of the entire prostate for histological analysis 65 . The TMA manufacturing process was described earlier in detail 66 . All histological sections stained with hematoxylin and eosin from all prostatectomy specimens were reviewed for the purpose of this study, and the positions of tumors were marked on the slides. One 0.6-mm tissue core was punched from a preselected area of each tumor and transferred in a TMA. The punch site was selected to contain the highest possible fraction of tumor cells. The tissues were distributed among 24 TMA blocks, each containing 144 to 522 tumor samples. Presence or absence of cancer tissue was validated by immunohistochemical AMACR and 34BE12 analysis on adjacent TMA sections. For internal controls, each TMA block also contained various control tissues, including normal prostate tissue.
Immunohistochemistry. Freshly cut TMA sections were immunostained in a single day and as one experiment. Primary antibody specific for BAZ2A (polyclonal, rabbit, Abnova, PAB21919; 1:150 dilution) was applied, and slides were deparaffinized and exposed to heat-induced antigen retrieval for 5 min in an autoclave at 121 °C in pH 7.8 Tris-EDTA buffer. Bound antibody was visualized using the EnVision kit (Dako). All stainings were analyzed by a single, experienced individual (K.G.). BAZ2A expression was predominantly localized to the nucleus, with lower expression levels in the cytoplasm of the cells. Nuclear BAZ2A staining was evaluated according to the following scoring system. The staining intensity (0, 1+, 2+ and 3+) and fraction of positive tumor cells were recorded for each tissue spot. A final immunohistochemistry score was built from these parameters as previously described [67] [68] [69] . Negative scores indicated the complete absence of staining; weak scores indicated a staining intensity of 1+ in ≤70% of tumor cells or a staining intensity of 2+ in ≤30% of tumor cells; moderate scores indicated a staining intensity of 1+ in >70% of tumor cells, a staining intensity of 2+ in >30% but ≤70% of tumor cells or a staining intensity of 3+ in ≤30% of tumor cells; and strong scores indicated a staining intensity of 2+ in >70% of tumor cells or a staining intensity of 3+ in >30% of tumor cells. As cytoplasmic BAZ2A staining was rare and typically associated with high nuclear staining levels, it was thus not considered for analysis.
Statistical analysis.
To calculate whether the proportion of genes regulated by both BAZ2A and EZH2 was expected by chance, we used a combination of permutation and Fisher tests to calculate P values. Briefly, the number of overlaps between BAZ2A-and EZH2-regulated genes was determined, and we then performed random permutation of EZH2-regulated genes and computed the overlap with BAZ2A-regulated genes using 1,000 iterations. From the permutation, the mean numbers of overlapped and non-overlapped genes were obtained. Fisher's exact test was used to evaluate the statistical difference from the expected pattern.
Multivariate analysis. Four multivariate analyses were performed evaluating the clinical relevance of BAZ2A expression in different scenarios (listed in Supplementary Table 9) . Scenario 1 used all postoperatively available parameters, including clinical stage, nodal status, margin status, preoperative PSA value and Gleason grade obtained on the resected prostate. Scenario 2 used all postoperatively available parameters with the exception of nodal status. The rationale for this approach was that lymphadenectomy is not a routine procedure in the surgical therapy of prostate cancer and that excluding nodal status in multivariate analysis increases case number. The next two scenarios tried to better model the preoperative situation. Scenario 3 included BAZ2A expression, preoperative PSA value, clinical stage and the Gleason grade obtained on the prostatectomy specimen. Because postoperative Gleason grade varies from preoperative Gleason grade, another multivariate analysis was added as scenario 4. In this scenario, the preoperative Gleason grade obtained on the original diagnostic biopsy was combined with the preoperative PSA value, clinical stage and BAZ2A expression.
